MedTrace Logo

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

NCT06243640 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 504

Last updated 2024-02-06

No results posted yet for this study

Summary

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Buagafuran capsules, 15mg/ capsule

Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;

DRUG

Buagafuran capsules mimic, 0mg/ capsule

Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;

Sponsors & Collaborators

  • R&G Pharma Studies Co.,Ltd.

    collaborator INDUSTRY

  • Beijing Union Pharmaceutical Factory Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-25
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06243640 on ClinicalTrials.gov